Prospective Observation of Cardiac Safety With Proteasome Inhibition
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary)
- Indications Heart failure; Multiple myeloma
- Focus Adverse reactions
- Acronyms PROTECT
- 14 Sep 2017 Planned End Date changed from 1 Dec 2017 to 28 Feb 2018.
- 14 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Jan 2018.
- 14 Sep 2017 Status changed from recruiting to active, no longer recruiting.